Table 3.

Indirect pathways depicting the most significant associations linking FLG mutations and airway disease outcomes

FLG status	1 and 2 years	4 years	10 years	18 years	Path co-efficient	P value
FLG-LOF →	Eczema→	Eczema→AAS→Asthma			3.17	0.002
FLG-LOF →	Eczema→	Eczema→AAS→	Asthma		3.14	0.002
FLG-LOF →	Eczema→	Eczema→AAS→	Asthma→	Asthma	3.08	0.002
FLG-LOF →	Eczema→	Eczema→ Rhinitis			2.65	0.008
FLG-LOF →	Eczema→	Eczema→AAS→	AAS→Rhinitis		3.27	0.001
FLG-LOF →	Eczema→	Eczema→AAS→	AAS→	Rhinitis	3.33	0.001

AAS: aeroallergen sensitization